Russia is a small (and faltering) economy, so I believe the revenue case is modest at best. Also, FDA approval will require a full Phase III trial, which requires a serious investment (not to mention a timeframe of years).
This is an "alternative" medicine, not a real therapeutic. It will be marketed and priced as such. Think vitamin pills.
